Insulin Degludec success in Types 1 and 2 Diabetes

Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego. The advantage of Insulin Degludec is that it has a duration of action that lasts up to 40 hours, unlike the 18 to 26 hours provided by current marketed long-acting insulins such as Insulin glargine and Insulin detemir. Data were from two, phase III, 52-week clinical trials, one with individuals with Type 1 Diabetes and one in individuals with Type 2 Diabetes.see Garber A. Insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine: 1-year results from randomized basal-bolus trial in people with type 2 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3582) and Insulin degludec improves long-term glycaemic control with less nocturnal see Heller S. Insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine: 1-year results from randomized basal-bolus trial in people with type 1 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3583).